When the Food and Drug Administration last week issued guidelines for investigative stem cell therapies, much of the attention fell to the agency’s vow to crack down further on unregulated clinics offering potentially unsafe treatments.
But the guidances also have plenty of ramifications for companies trying to bring to market innovative and legitimate stem cell treatments by moving them through clinical trials and getting them approved by the FDA.
About the Author Reprints
